SLT-VEGF Reduces Lung Metastases and Improves Survival in Melanoma
Author Information
Author(s): Ackerman Rachel, Backer Joseph M., Backer Marina, Skariah Sini, Hamby Carl V.
Primary Institution: New York Medical College
Hypothesis
SLT-VEGF could be a promising adjuvant therapy to inhibit or prevent outgrowth of metastatic foci after excision of aggressive primary melanoma lesions.
Conclusion
SLT-VEGF treatment led to fewer tumor recurrences, reduced lung metastasis, and improved survival in a melanoma model.
Supporting Evidence
- SLT-VEGF treatment reduced the incidence of lung metastasis.
- SLT-VEGF treatment led to fewer tumor recurrences after primary tumor removal.
- Survival was significantly improved in SLT-VEGF treated mice compared to controls.
Takeaway
SLT-VEGF is a special treatment that helps stop cancer from coming back and spreading to the lungs after surgery.
Methodology
The study used NCR athymic nude mice inoculated with human melanoma cells and treated them with SLT-VEGF to assess tumor growth, recurrence, and metastasis.
Limitations
The study's findings may not be applicable to all types of tumors or in different mouse models with longer dormancy periods.
Participant Demographics
NCR athymic nude mice were used in the study.
Statistical Information
P-Value
p = 0.007 for tumor recurrence, p = 0.038 for lung metastasis, p = 0.002 for survival
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website